Results 61 to 70 of about 333,932 (156)
Among 190 older adults who experienced AKI‐related hospitalization after SGLT2 inhibitor initiation, 31.1% were hospitalized within 30 days. In an independent single‐center cohort, sustained early eGFR decline was associated with older age and use of one or two triple‐whammy‐related drug classes.
Kazuya Hiura +6 more
wiley +1 more source
The Sudden Cardiac Death Continuum. Message 3
BACKGROUND Endothelial dysfunction (ED), formed under the influence of risk factors (RF), is the leading link in the pathogenesis of cardiovascular diseases (CVD), sudden cardiac death (SCD).
A. Yu. Lazutkina
doaj +1 more source
Ipertensione arteriosa, continuum cardiovascolare e ruolo clinico dei sartanii [PDF]
The cardiovascular and cardiorenal continuum comprises the transition from cardiovascular risk factors to endothelial dysfunction and atherosclerosis, to chronic congestive heart failure, and-stage renal disease or premature death.
Destro, Maurizio
core +1 more source
ABSTRACT Aims/Introduction To evaluate the real‐world effectiveness and safety of enavogliflozin as a single‐pill formulation (Enavo group; enavogliflozin 0.3 mg) or fixed‐dose combination with metformin (EnavoMet group; enavogliflozin 0.3 mg/metformin 1000 mg) in patients with type 2 diabetes (T2DM) in Korean primary care.
Hyunji Sang +8 more
wiley +1 more source
Abstract The antihypertensive mechanism of sodium–glucose cotransporter 2 (SGLT2) inhibitors has been traditionally attributed to osmotic diuresis. However, emerging evidence reveals multifaceted mechanisms beyond diuresis, including regulation of the renin–angiotensin–aldosterone system, sympathetic nervous system suppression, ion homeostasis ...
Chunxiang Xu +5 more
wiley +1 more source
Therapeutic Management of Cardiorenal Syndrome in A Non-Descript Dog
<p><span>Cardiorenal syndrome is a multi-organ disorder of heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other. Cardiorenal syndrome occur mostly due to decreased glomerular
Therapeutic Management of Cardiorenal Syndrome in A Non-Descript Dog
core +1 more source
Bibliometric analysis of 3736 publications (2004–2025) reveals rapid growth in GLP‐1–based T2DM research. The US leads, with Novo Nordisk and Eli Lilly as top contributors. Thematic shifts from glycemic control toward cardiovascular‐kidney‐metabolic outcomes and real‐world evidence, driven by landmark trials like LEADER and REWIND.
Yanbing Wang +6 more
wiley +1 more source
A narrative review of dietary patterns in cardiovascular-kidney-metabolic syndrome
Driven by the global rise in obesity and lifestyle transitions, cardiovascular-kidney-metabolic (CKM) syndrome has emerged as a pathophysiological continuum characterized by metabolic dysregulation and involving multi-organ interactions.
Luo Lv +6 more
doaj +1 more source
New Advances in Cardiorenal Syndrome—Ready for Prime Time?
Cardiorenal Syndrome has become one pressing issue as far as hospitalizations are concerned [...
Pliquett, Rainer U., Rainer U. Pliquett
core +1 more source
Abstract Background Clinical services for adults with early‐onset type 2 diabetes (EOT2D) are in urgent need of improvement. Methods We evaluated a multi‐disciplinary clinic for individuals with EOT2D at high risk (HbA1c >9%/triglyceride >20 mmol/L), providing 2–3 flexibly arranged consultations per individual between March 2024 and September 2025 ...
Jonathan Goldney +14 more
wiley +1 more source

